8-(tert-butyl-dimethyl-silyloxy)-11,12-dihydro-5H-6,13-dioxa-benzo[3,4]cyclohepta[1,2-a]naphthalen-5-ol | 554430-73-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 8-(tert-butyl-dimethyl-silyloxy)-11,12-dihydro-5H-6,13-dioxa-benzo[3,4]cyclohepta[1,2-a]naphthalen-5-ol
• 英文别名: 15-[Tert-butyl(dimethyl)silyl]oxy-8,18-dioxatetracyclo[9.8.0.02,7.012,17]nonadeca-1(11),2,4,6,12(17),13,15-heptaen-19-ol
• CAS: 554430-73-8
• 化学式: C₂₃H₂₈O₄Si
• 分子量: 396.558
• InChiKey: AVBWRPTWGXIFAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.47
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  47.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-(tert-butyl-dimethyl-silyloxy)-11,12-dihydro-5H-6,13-dioxa-benzo[3,4]cyclohepta[1,2-a]naphthalen-5-ol 、 [2-(4-iodophenoxy)ethyl]dimethylamine 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Identification and Structure−Activity Relationships of Chromene-Derived Selective Estrogen Receptor Modulators for Treatment of Postmenopausal Symptoms

  摘要：

  As part of it program aimed at the development of selective estrogen receptor modulators (SERMs), novel chromene scaffolds, benzopyranobenzoxapanes, were discovered. Many compounds showed binding affinity as low as 1.6-200 nM, displayed antagonist behaviors in the MCF-7 human breast adenocarcinoma cell line its well in Ishikawa cell line with IC50 values in the range 0.2-360 nM. On the basis of the side chain substitution, various compounds demonstrated strong inhibitory activity in anti-uterotropic assay. Compound 7-(R) and its major metabolites 5-(R) and 6-(R) were evaluated in several in vivo models of estrogen action. Relative to a full estrogen agonist (ethynyl estradiol) and file SERM raloxifene, 7-(R) wits found to be it potent SERM that behaved its antagonist in the uterus and exhibited estrogen agonistic activity on bone, plasma lipids, hot flush, and vagina. The overall pharmacokinetic profile and stability were Significantly improved compared to those of the phase 2 development compound 9-(R).

  DOI：

  10.1021/jm900146e
• 作为产物：
  描述：

  8-(tert-butyl-dimethyl-silyloxy)-11,12-dihydro-6,13dioxa-benzo[3,4]cyclohepta[1,2-a]naphthalen-5-one 在 二异丁基氢化铝 作用下， 以 甲苯 为溶剂， 反应 3.0h， 生成 8-(tert-butyl-dimethyl-silyloxy)-11,12-dihydro-5H-6,13-dioxa-benzo[3,4]cyclohepta[1,2-a]naphthalen-5-ol
  参考文献：
  名称：

  Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators

  摘要：

  本发明涉及包含杂原子的新型四环衍生物，包含它们的药物组合物，它们在治疗和/或预防由一个或多个雌激素受体介导的疾病中的应用，以及它们的制备过程。发明中的化合物在治疗和/或预防与雌激素耗竭相关的疾病中是有用的，如热潮红、阴道干涩、骨量减少和骨质疏松症；激素敏感性癌症和乳腺、子宫内膜、宫颈和前列腺的增生；子宫内膜异位症、子宫肌瘤、骨关节炎，并且作为避孕剂，单独使用或与孕激素或孕激素拮抗剂结合使用。

  公开号：

  US20030216463A1

文献信息

• Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
  申请人：——

  公开号：US20030216463A1

  公开（公告）日：2003-11-20

  The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and/or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and/or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

  本发明涉及包含杂原子的新型四环衍生物，包含它们的药物组合物，它们在治疗和/或预防由一个或多个雌激素受体介导的疾病中的应用，以及它们的制备过程。发明中的化合物在治疗和/或预防与雌激素耗竭相关的疾病中是有用的，如热潮红、阴道干涩、骨量减少和骨质疏松症；激素敏感性癌症和乳腺、子宫内膜、宫颈和前列腺的增生；子宫内膜异位症、子宫肌瘤、骨关节炎，并且作为避孕剂，单独使用或与孕激素或孕激素拮抗剂结合使用。
• Identification and Structure−Activity Relationships of Chromene-Derived Selective Estrogen Receptor Modulators for Treatment of Postmenopausal Symptoms
  作者：Nareshkumar Jain、Jiayi Xu、Ramesh M. Kanojia、Fuyong Du、Guo Jian-Zhong、Emmanuel Pacia、Muh-Tsann Lai、Amy Musto、George Allan、Michael Reuman、Xun Li、DoWon Hahn、Martin Cousineau、Sean Peng、David Ritchie、Ronald Russell、Scott Lundeen、Zhihua Sui

  DOI：10.1021/jm900146e

  日期：2009.12.10

  As part of it program aimed at the development of selective estrogen receptor modulators (SERMs), novel chromene scaffolds, benzopyranobenzoxapanes, were discovered. Many compounds showed binding affinity as low as 1.6-200 nM, displayed antagonist behaviors in the MCF-7 human breast adenocarcinoma cell line its well in Ishikawa cell line with IC50 values in the range 0.2-360 nM. On the basis of the side chain substitution, various compounds demonstrated strong inhibitory activity in anti-uterotropic assay. Compound 7-(R) and its major metabolites 5-(R) and 6-(R) were evaluated in several in vivo models of estrogen action. Relative to a full estrogen agonist (ethynyl estradiol) and file SERM raloxifene, 7-(R) wits found to be it potent SERM that behaved its antagonist in the uterus and exhibited estrogen agonistic activity on bone, plasma lipids, hot flush, and vagina. The overall pharmacokinetic profile and stability were Significantly improved compared to those of the phase 2 development compound 9-(R).